New drugs in gynecologic oncology.
New agents with activity in recurrent epithelial ovarian cancer include the taxoids (paclitaxel and docetaxel), camptothecins (topotecan and irinotecan), gemcitabine, and oxaliplatin. In front-line therapy, the Gynecologic Oncology Group has shown that paclitaxel prolongs survival. In recurrent squamous carcinoma of the cervix, irinotecan has an objective response rate of 15%-24%. Both paclitaxel and docetaxel also show modest activity. Of these new agents, only paclitaxel has been evaluated in carcinoma of the endometrium, reporting a response rate of 35%.
NCIC Clinical Trials Group, Queen's University, Kingston, Ontario, Canada.
E A
EA
Eisenhauer
J B
JB
Vermorken
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use; D002166:Camptothecin / Q000627:therapeutic use; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy; D002986:Clinical Trials as Topic; D003841:Deoxycytidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D016889:Endometrial Neoplasms / Q000188:drug therapy; D005260:Female; D005833:Genital Neoplasms, Female / Q000188:drug therapy*; D006801:Humans; D010051:Ovarian Neoplasms / Q000188:drug therapy; D017671:Platinum Compounds / Q000627:therapeutic use; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy; D000093542:Gemcitabine
D000970:Antineoplastic Agents; D000972:Antineoplastic Agents, Phytogenic; D017671:Platinum Compounds; D003841:Deoxycytidine; D002166:Camptothecin; D000093542:Gemcitabine